Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Gastric Mucosa-associated Lymphoid Tissue (MALT); Lymphoma Idiopathic Thrombocytopenic Purpura; Early Gastric Cancer; Gastric Ulcer; Duodenal Ulcer

Study type: Observational

Funder types: Industry

Identifiers

NCT01435525

D961HC00011

Details and patient eligibility

About

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

Full description

Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication

Enrollment: 369 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric ulcer
• Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for duodenal ulcer
• Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for gastric MALT lymphoma
• Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for idiopathic thrombocytopenic purpura
• Triple therapy for H.pylori eradication to stomach started after endoscopic treatment for early gastric cancer

Exclusion criteria

• H.pylori negative at the time when the triple therapy is started

Trial design

369 participants in 1 patient group

Nexium